A Randomized, Double‐Blind, Double‐Dummy, Multicenter Trial of Voriconazole and Fluconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients
R. Ally(Chris Hani Baragwanath Hospital), Michael R. Hodges(Pfizer (United States)), Dirk Schürmann(Humboldt-Universität zu Berlin), Koldo Aguirrebengoa(Hospital de Cruces), Giampiero Carosi(Institute for Scientific Interchange), B. Dupont(Délégation Paris 5), Peter F. Troke, Wolfgang Kreisel(University of Freiburg), Alain Romero(Pfizer (United Kingdom))
Cited by 334
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007
|Clinical Microbiology and Infection|2011|752
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
|Clinical Infectious Diseases|2003|680
Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign
|Clinical Infectious Diseases|2007|585